Electrophysiologic basis for the antiarrhythmic actions of ranolazine.
Electrophysiologic basis for the antiarrhythmic actions of ranolazine.
复制标题
DOI:
10.1016/j.hrthm.2011.03.045
复制
发表时间:
2011-08
期刊:
影响因子:
5.5
通讯作者:
Belardinelli, Luiz
中科院分区:
文献类型:
--
作者:
Antzelevitch, Charles;Burashnikov, Alexander;Sicouri, Serge;Belardinelli, Luiz
关键词:
Ranolazine is an FDA-approved anti-anginal agent. Experimental and clinical studies have shown that ranolazine has anti-arrhythmic effects in both ventricles and atria. In the ventricles, ranolazine can suppress arrhythmias associated with acute coronary syndrome, long QT, heart failure, ischemia, and reperfusion. In atria, ranolazine effectively suppresses atrial tachyarrhythmias and fibrillation (AF). Recent studies have shown that the drug may be effective and safe in suppressing AF when used as a pill-in-the pocket approach, even in patients with structurally compromised hearts, warranting further study. The principal mechanism underlying ranolazine’s antiarrhythmic actions is thought to be primarily via inhibition of late INa in the ventricles, and via use-dependent inhibition of peak INa and IKr in the atria. Short and long term safety of ranolazine has been demonstrated in the clinic, even in patients with structural heart disease. This review summarizes the available data regarding the electrophysiological actions, and anti-arrhythmic properties of ranolazine in preclinical and clinical studies.
登录
查看更多内容
影响因子:
1.3
作者:
Antzelevitch, Charles;Burashnikov, Alexander
通讯作者:
Burashnikov, Alexander
影响因子:
5.5
作者:
Burashnikov, Alexander;Belardinelli, Luiz;Antzelevitch, Charles
通讯作者:
Antzelevitch, Charles
影响因子:
5.5
作者:
Blana, Andreas;Kaese, Sven;Fabritz, Larissa
通讯作者:
Fabritz, Larissa
影响因子:
10.8
作者:
Fabritz, Larissa;Damke, Dierk;Kirchhof, Paulus
通讯作者:
Kirchhof, Paulus
DOI:
10.1111/j.1540-8167.2006.00388.x
发表时间:
2006-05-01
影响因子:
2.7
作者:
Antzelevitch, Charles;Belardinelli, Luiz
通讯作者:
Belardinelli, Luiz